EPV-CoV19: The Healthcare Worker Vaccine

Discover

EpiVax is dedicated to the discovery and development of a COVID-19 vaccine

Read More

Press Release: Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE Platform

Read More

Press Release: EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries

Read More

Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

Read More

Press Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

Read More

Press Release: EpiVax Accelerates COVID-19 Vaccine Development with UGA’s Center for Vaccines and Immunology

Read More

Improving human health everywhere.

Science without fear.

Discover
immuno screening

Immunogenicity Assessment

deimmunization

Deimmunization

lab services

Lab Services

pipeline

Pipeline

We are dedicated to applying our tools (in-silico, in-vitro and in-vivo) to re-engineering therapeutic proteins and to designing new vaccines. Discover

We take pride in our ability to put our combined intelligence, experience, and creativity to work to improve human health. Open minds, creative thought and natural curiosity lead to paradigm shifts. Contact us today to learn more.

Corporate Office/Laboratory:
EpiVax, Inc.
188 Valley Street, Suite 424, Providence, RI 02909 USA
ph: 401.272.2123 fax: 401.272.7562

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here